Evonile Pharma, formerly known as Novartis India, has announced plans for a major capital raise through a rights issue totalling INR 900 crore. The formal approval for the corporate action was granted on 8 October 2026. While specific timelines, entitlement ratios, and pricing details are yet to be finalised and published in the official letter of offer, the announcement has drawn significant attention from market participants following the company’s rebranding and transition.
Corporate Overview and Business Model
Operating primarily in the Indian market, the company focuses on the wholesale, import, and distribution of pharmaceutical and medical goods. Its operational framework relies on an asset-light, import-driven distribution model. In fiscal year 2024, approximately 99% of the company’s revenue originated from the sale of traded goods rather than direct domestic manufacturing facilities.
The product portfolio targets specialised therapeutic categories, including pain management, neurosciences, and organ transplantation immunology. Well-known legacy brands managed by the entity include Voveran®, Tegrital®, Exelson®, alongside vital transplant maintenance therapies such as Neoral®, Sandimmun®, and Myfortic®. Notably, the transplant maintenance product basket exhibited operational resilience, expanding by 11% year-on-year during FY24.
To widen market reach and enhance field force efficiency, the company maintains a strategic sales and distribution alliance with Dr. Reddy’s Laboratories covering major heritage product lines such as the Voveran® and Calcium ranges. Additionally, the corporate entity supports global research initiatives through advanced Development Hubs situated in Mumbai and Hyderabad. These facilities employ over 350 specialised scientists dedicated to developing new chemical entities across oncology, cardiovascular, and immunology fields. Swiss-based Novartis AG currently retains a 70.7% promoter stake, which remains under strategic review, alongside promoters Waverise Investments and Chryscapital Fund X.
Rights Issue Structure and Parameters
The proposed capital raising initiative aims to secure INR 900 crore through a partly paid-up rights issue structure. Equity shares hold a face value of INR 5 per share, and the resulting shares will be listed on both the BSE and NSE. MUFG Intime (Link Intime) India Private Limited acts as the official registrar for the issue.
Financial Performance Overview
Financial records indicate mixed performance over the preceding three fiscal years on a standalone basis. Revenue registered at INR 335 crore in FY24, improved to INR 356 crore in FY25, and settled at INR 354 crore in FY26. Operational revenues experienced a temporary contraction of roughly 12% year-on-year during FY24, largely attributed to National List of Essential Medicines (NLEM) price revisions impacting nine major branded lines.
Total expenses were recorded at INR 270 crore in FY24, INR 265 crore in FY25, and INR 260 crore in FY26. Net income stood at INR 85 crore for FY24, peaked at INR 101 crore in FY25, and registered at INR 93 crore for FY26.
Objectives of the Rights Issue
The proceeds generated from the capital raise are earmarked for specific corporate requirements:
- Repayment or prepayment, whether partial or full, of certain outstanding borrowings taken by the company, including accrued interest and associated penalties, amounting to INR 800 crore.
- General corporate purposes.
Market and Business Analysis
Company and Business Impact
The transition from Novartis India to Evonile Pharma marks a pivotal phase in the enterprise’s operational lifecycle. The heavy reliance on traded goods—accounting for 99% of FY24 turnover—highlights an asset-light model that protects the balance sheet from heavy capital expenditures on manufacturing plants. However, regulatory pressures, such as price revisions under the NLEM affecting key brands, introduce revenue volatility, evidenced by the 12% top-line contraction in FY24.
Despite regulatory headwinds, core therapeutic segments like transplant immunology continue to display steady demand, growing at 11% year-on-year in FY24. The strategic partnership with Dr. Reddy’s Laboratories provides an effective mechanism to defend market share for legacy brands like Voveran® by leveraging an expanded distribution network. Furthermore, the presence of dedicated R&D hubs housing over 350 scientists provides technological depth inherited from Swiss-based Novartis AG.
Financial and Valuation Analysis
Based on the reported standalone financial data, the company demonstrates consistent profitability despite fluctuating revenues. Net income moved from INR 85 crore in FY24 to INR 101 crore in FY25, before moderating to INR 93 crore in FY26. Expense optimisation has been a notable feature, with total expenses declining steadily from INR 270 crore in FY24 down to INR 260 crore in FY26, which helped cushion net margins even as revenues plateaued around INR 354 crore to INR 356 crore.
The decision to deploy INR 800 crore of the INR 900 crore rights issue towards debt servicing indicates a clear management strategy to strengthen the balance sheet by lowering interest burdens. With the equity share quoted around INR 1,986.40 per share at the time of rights approval on 8 October 2026, market participants will be closely watching the final discount rate once the pricing and entitlement ratio are officially released.
| Financial Metric | FY 2024 (INR Crore) | FY 2025 (INR Crore) | FY 2026 (INR Crore) | Analysis |
|---|---|---|---|---|
| Revenue | 335 | 356 | 354 | Revenue recovered in FY25 following NLEM price revisions but stabilized in FY26. |
| Expenses | 270 | 265 | 260 | Disciplined cost management resulted in a steady reduction in operational expenses over three years. |
| Net Income | 85 | 101 | 93 | Profitability peaked in FY25 before experiencing a mild contraction in FY26. |
Key Takeaways
- Evonile Pharma announced a rights issue aiming to raise INR 900 crore following approval on 8 October 2026.
- The majority of the proceeds, approximately INR 800 crore, will be utilized to repay or prepay outstanding borrowings and accrued interest.
- Standalone revenue stood at INR 354 crore in FY26, compared to INR 356 crore in FY25 and INR 335 crore in FY24.
- Net income registered at INR 93 crore in FY26, following a high of INR 101 crore in FY25.
- The company operates an import-driven distribution model with a 70.7% promoter stake held by Novartis AG under strategic review.
- Detailed timelines, pricing, and entitlement ratios remain to be finalized and announced in the official Letter of Offer.
Frequently Asked Questions
The total size of the rights issue is INR 900 crore.
The rights issue was approved on 8 October 2026.
The primary objective is the repayment or prepayment of certain outstanding borrowings and accrued interest amounting to INR 800 crore, alongside general corporate purposes.
The standalone net income for FY26 was INR 93 crore.
The registrar for the rights issue is MUFG Intime (Link Intime) India Private Limited.
The face value is INR 5 per share.